Results 71 to 80 of about 6,036 (190)

Optimising coronary reperfusion in acute myocardial infarction: the role of primary angioplasty [PDF]

, 2007
PhDThrombolysis remains the predominant reperfusion strategy for ST segment elevation myocardial infarction (STEMI) in the United Kingdom. Although primary angioplasty may offer superior outcomes, the logistics of delivering this therapy in the UK ...
Smith, Elliot J
core   +1 more source

Early and long-term outcome of elective stenting of the infarct-related artery in patients with viability in the infarct-area: Rationale and design of the Viability-guided Angioplasty after acute Myocardial Infarction-trial (The VIAMI-trial)

Current Controlled Trials in Cardiovascular Medicine, 2004
Background Although percutaneous coronary intervention (PCI) is becoming the standard therapy in ST-segment elevation myocardial infarction (STEMI), to date most patients, even in developed countries, are reperfused with intravenous thrombolysis or do ...
Visser Cees A, Bronzwaer Jean GF, Kamp Otto, Veen Gerrit, van Loon Ramon B, Visser Frans C   +5 more
doaj   +1 more source

Clinical impact of abciximab on long-term outcome after complex coronary angioplasty

, 2003
Glycoprotein IIb/IIIa receptor antagonists, such as abciximab, are used to reduce major adverse cardiac events (MACES) in patients undergoing percutaneous transluminal coronary angioplasty.
Versteeg, DIK, Tio, RA, Wijpkema, JS, Van Boven, AJ, Jessurun, GAJ, Hautvast, RWM   +5 more
core   +1 more source

Investigation of interaction of human platelet membrane components with anticoagulant drugs Abciximab and Eptifibatide

Folia Histochemica et Cytobiologica, 2010
Abciximab (Abci) and eptifibatide (Epti) are antiaggregate drugs which may reduce thrombotic complications inacute coronary syndromes. The aim of this work was the investigation of the interaction between the phospholipid-GPIIb/IIIa glycoprotein complex ...
Ewa Gorodkiewicz, Anna Sankiewicz, Zbigniew A. Figaszewski   +2 more
doaj  

Antiplatelet medications in acute coronary syndromes and percutaneous coronary interventions: focus on tirofiban

Кардиоваскулярная терапия и профилактика, 2008
The review presents literature data on the key role of platelet aggregation (PA) for intracoronary thrombogenesis in various acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI).
T. A. Batyraliev, D. V. Preobrazhensky, D. V. Fetzer, B. A. Sidorenko, S. A. Pataraya   +4 more
doaj  

High bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI - The tamip study

Heart Views, 2012
Background: Primary percutaneous coronary intervention (PCI) has been shown to be an effective therapy for patients with acute myocardial infarction (MI). Glycoprotein (GP) IIb/IIIa receptor blockers reduce thrombotic complications in patients undergoing
Mohammed A Balghith
doaj   +1 more source

Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes [PDF]

, 2017
Aims The safety and efficacy of abciximab in addition to low-molecular-weight-heparin as the primary medical treatment of acute coronary syndromes has not previously been investigated.
James, S., Simoons, M.L., Kontny, F., Armstrong, P., Husted, S., Pfisterer, M., Niemminen, M., Wallentin, L., Califf, R.   +8 more
core  

Intracranial bleeding mimicking an extensive acute myocardial infarction with reversible apical ballooning and systolic left ventricular dysfunction. A case report

Monaldi Archives for Chest Disease, 2016
A novel syndrome with transient asynergy of the apical segments of the left ventricle, also known as tako-tsubo cardiomyopathy, has been recently described and presents characteristics and effects similar to acute myocardial infarction.
Antonio D’Aloia, Enrico Vizzardi, Pompilio Faggiano, Claudia Fiorina, Livio Dei Cas   +4 more
doaj   +1 more source

Beneficial effect of post-procedural abciximab in patients undergoing primary coronary angioplasty and presenting with the no-reflow phenomenon

, 2008
We sought to investigate the effect of post-procedural abciximab on clinical outcome of patients presenting the no-reflow phenomenon after primary angioplasty.
PICCHI A, MONDILLO, SERGIO, MARZILLI M., SINICROPI G, MARZILLI, MARIO, ZACA V, PIERLI C, MONDILLO S, CASINI S, BUTI A, FOCARDI M, FINESCHI M   +11 more
core   +1 more source

Terapia con anticuerpos monoclonales en Cardiología y Medicina Interna

Revista Colombiana de Cardiología, 2016
La terapia biológica basada en anticuerpos monoclonales, constituyen una nueva herramienta terapéutica, que de la mano del desarrollo de la biología molecular permiten intervenir puntos claves en la etiopatogenia de la enfermedad, permitiendo una terapia
Christian David Adams-Sánchez, Gabriel Jaime Tobón-García   +1 more
doaj   +1 more source